Bayer, adivo to develop therapeutic antibodiesApril 17, 2019Bayer Animal Health and adivo have signed an agreement to develop therapeutic antibodies for companion animals. The collaboration may be good news for veterinary medicine. Although the use of therapeutic antibodies is not widespread, they offer a variety of healing options for diseases that still cannot be treated with current technology. "Today's agreement is another example of how we realize our innovation strategy," says Douglas Hutchens, DVM, PhD, Bayer Animal Health's head of drug …
SPONSORED CONTENTA brighter future for parvovirus patientsOur Canine Parvovirus Monoclonal Antibody helps puppies recover faster, and current users report reductions in clinic stress during parvo treatment.1,2 Find out why veterinary teams are embracing CPMA. + Read More
